UCB (OTCMKTS:UCBJY) Shares Gap Up – Should You Buy?

UCB SA (OTCMKTS:UCBJY)’s share price gapped up prior to trading on Friday . The stock had previously closed at $145.76, but opened at $151.28. UCB shares last traded at $151.67, with a volume of 5,833 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts have commented on UCBJY shares. Zacks Research lowered UCB from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 13th. Wolfe Research raised shares of UCB to a “strong-buy” rating in a research report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy”.

UCB Trading Down 0.3%

The firm has a 50-day moving average of $145.09 and a 200 day moving average of $146.40. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.